The improved version of this drug, ARS-1620, demonstrated the tumor growth control in a KRAS G12C xenograft model [49] by its additional H-bond interaction with H95 in the switch pocket and a more favorable alignment of the warhead toward C12 (Figure 4c) [50]. This evidence concerns the gene KRAS and neoplasm.